Klaria Pharma

First quarter of 2024

The group in total

- Net sales 9.0 MSEK (0.1 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 3.4 MSEK (4.6 MSEK)

- Profit after tax amounted to -1.6 MSEK (-11.9 MSEK)

- Earnings per share for the quarter amounted to -0.01 SEK (-0.11 SEK)

- Cash flow from operating activities amounted to 0.9 MSEK (-7.8 MSEK)

- Liquid assets on the balance sheet date amounted to 1.5 MSEK (0.9 MSEK)

- Equity as of March 31 amounted to 1.7 MSEK 29.2 MSEK)